搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按时间排序
按相关度排序
centerforbiosimilars
1 天
Retrospective Study Shows Bevacizumab Biosimilar Efficacy in NSCLC
Bevacizumab biosimilars have the potential to expand access and reduce costs without compromising patient outcomes in ...
腾讯网
1 天
突破 EGFR-TKI 耐药困境,Dato-DXd 关键研究汇总分析入选 LBA,将亮相 ESMO ...
2024 年 12 月 6 日 - 8 日,欧洲肿瘤内科学会亚洲年会(ESMO Asia)将在新加坡盛大召开。本届会议将汇聚全球专家学者,集中展示和讨论肿瘤学领域的最新科学和临床进展,为肿瘤领域带来一场学术盛宴。此次会议中,「Dato-DXd ...
healthandpharma
2 天
How AI is Shaping Drug Discovery: LP-300's Breakthrough in Lung Cancer Treatment
AI-Enabled Drug Discovery is on the verge of a new revolution, with the first data emerging from exciting research indicating ...
3 天
More than 95% of EGFR lung cancer patients have developed anticancer drug resistance ...
A technology has been developed that can analyze tumor mutations in lung cancer patients to confirm drug resistance to ...
BioWorld
4 天
NMPA clears Alpha’s oral EGFR-TKI for NSCLC with brain metastases
China’s drug regulator approved Alpha Biopharma Ltd.’s EGFR tyrosine kinase inhibitor (TKI), Zorifer (zorifertinib hydrochloride tablets; AZD-3759), as a first-line treatment for EGFR-mutated ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈